赛马鲁肽
医学
怀孕
产科
孕早期
回顾性队列研究
肥胖
糖尿病
妇科
妊娠期
2型糖尿病
内科学
内分泌学
利拉鲁肽
生物
遗传学
出处
期刊:Obstetric Medicine
[SAGE Publishing]
日期:2025-06-04
卷期号:: 1753495X251346330-1753495X251346330
被引量:2
标识
DOI:10.1177/1753495x251346330
摘要
Background and objective To review pregnancy outcomes in women exposed to semaglutide during early pregnancy. Methods A retrospective review of an obstetric database at a tertiary obstetric hospital in Brisbane, Australia. Results Thirteen women were exposed to semaglutide in first trimester. One infant had significant cardiac anomalies in the setting of very poor maternal glycaemic control in first trimester, as well as maternal obesity and hypertension. Conclusion This study adds to the growing literature suggesting there is no increased risk of major congenital anomalies following first trimester exposure to semaglutide, however, until larger studies are available to confirm these findings, reproductive-age women using semaglutide should practice effective contraceptive methods. Preconception counselling of all women with diabetes mellitus is critical to avoid adverse pregnancy outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI